Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Algiax Pharmaceuticals Expands Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain with 12 New Clinical Sites in Belgium and France | ||
By: PR Newswire Association LLC. - 11 Apr 2024 | Back to overview list |
|
DÜSSELDORF, Germany, April 11, 2024 /PRNewswire/ -- Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain. Based on last year's positive mid-enrollment interim analysis and confirmed financial commitment from its investors, the company is pleased to announce the initiation of 12 new clinical sites in Belgium and France as part of its Phase 2a Randomized Controlled Trial (RCT) - AP-325.04 study. With these additions, the total number of active sites in the study has reached 25, including sites in the Czech Republic and Spain. The expansion of our clinical trial into Belgium and France marks a significant milestone in our commitment to advancing pain management research and providing effective treatments for patients suffering from chronic neuropathic pain conditions. We are delighted to report the enrollment of the first French patients at the esteemed sites of Prof. Pluchon in Roche-sur-Yon and Prof. Attal at the Hôpital Ambroise Paré, Boulogne-Billancourt. In Belgium, our study has successfully enrolled patients with chronic post-operative neuropathic pain at the sites of Dr. van Boxem at ZOL in Genk and Prof. Morlion at UZ Leuven. This achievement underscores our dedication to collaborating with leading clinicians and researchers to bring innovative therapies to those in need. "We are excited about the progress of our Phase 2a study and the expansion of our study into Belgium and France," said Ingo Lehrke, Ph.D., Chief Executive Officer of Algiax Pharmaceuticals. "The addition of these new clinical sites further strengthens our efforts to present topline efficacy readouts and an in-depth safety analysis following study conclusion in Q4 2024." About AP-325 About Algiax CONTACTS: Logo - https://mma.prnewswire.com/media/2381511/Algiax_Logo.jpg View original content to download multimedia:https://www.prnewswire.com/news-releases/algiax-pharmaceuticals-expands-phase-2a-study-with-lead-candidate-ap-325-in-chronic-neuropathic-pain-with-12-new-clinical-sites-in-belgium-and-france-302110636.html SOURCE Algiax Pharmaceuticals GmbH |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |